Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy

Radiotherapy and Oncology

Volumn 118, Issue 3, 2016, Pages 453-459

  Wink, Krista C J ^a   Belderbos, José S A ^b   Dieleman, Edith M T ^c   Rossi, Maddalena ^b   Rasch, Coen R N ^c   Damhuis, Ronald A M ^d   Houben, Ruud M A ^a   Troost, Esther G C ^a,e,f,g  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Netherlands Comprehensive Cancer Organization   (Netherlands)

^e INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^f Helmholtz Zentrum Dresden Rossendorf   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Chemotherapy; Diabetes; Metformin; NSCLC; Radiotherapy

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; ETOPOSIDE; METFORMIN; NAVELBINE; ANTIDIABETIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CASE CONTROL STUDY; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NETHERLANDS; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CHEMORADIOTHERAPY; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; METFORMIN; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84961909168     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.01.012     Document Type: Article

References (44)

1. International Diabetes Federation Guideline Development G Global guideline for type 2 diabetes Diabetes Res Clin Pract 104 2014 1 52
2. D. Margel, D.R. Urbach, L.L. Lipscombe, and et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes J Clin Oncol 31 2013 3069 3075
3. D.E. Spratt, C. Zhang, Z.S. Zumsteg, X. Pei, Z. Zhang, and M.J. Zelefsky Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality Eur Urol 63 2013 709 716
4. R.J. Dowling, P.J. Goodwin, and V. Stambolic Understanding the benefit of metformin use in cancer treatment BMC Med 9 2011 33
5. Y. Storozhuk, S.N. Hopmans, T. Sanli, and et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK Br J Cancer 108 2013 2021 2032
6. V.E. Zannella, A. Dal Pra, H. Muaddi, and et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response Clin Cancer Res 19 2013 6741 6750
7. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
8. J.P. Harris, J.D. Murphy, A.L. Hanlon, Q.T. Le, B.W. Loo Jr., and M. Diehn A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer Int J Radiat Oncol Biol Phys 88 2014 872 884
9. A. Auperin, C. Le Pechoux, J.P. Pignon, and et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients Ann Oncol 17 2006 473 483
10. N. Bayman, F. Blackhall, P. McCloskey, P. Taylor, and C. Faivre-Finn How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer? Lung Cancer 83 2014 117 125
11. M. Saunders, S. Dische, A. Barrett, A. Harvey, G. Griffiths, and M. Palmar Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial CHART Steering committee Radiother Oncol 52 1999 137 148
12. A. Mauguen, C. Le Pechoux, M.I. Saunders, and et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis J Clin Oncol 30 2012 2788 2797
13. J.D. Bradley, R. Paulus, R. Komaki, and et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study Lancet Oncol 16 2015 187 199
14. B.X. Tan, W.X. Yao, J. Ge, and et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes Cancer 117 2011 5103 5111
15. S.F. Teixeira, S. Guimaraes Idos, K.P. Madeira, R.D. Daltoe, I.V. Silva, and L.B. Rangel Metformin synergistically enhances antiproliferative effects of cisplatin and etoposide in NCI-H460 human lung cancer cells J Bras Pneumol 39 2013 644 649
16. F. Morgillo, F.C. Sasso, C.M. Della Corte, and et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines Clin Cancer Res 19 2013 3508 3519
17. A. van Baardwijk, S. Wanders, L. Boersma, and et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer J Clin Oncol 28 2010 1380 1386
18. A.L. Uitterhoeve, J.S. Belderbos, M.G. Koolen, and et al. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer Eur J Cancer 36 2000 592 600
19. A.M. Dingemans, G. Bootsma, A. van Baardwijk, and et al. A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer J Thorac Oncol 9 2014 710 716
20. M.M. van den Heuvel, W. Uyterlinde, A.D. Vincent, and et al. Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating Radiother Oncol 110 2014 126 131
21. W. van Elmpt, D. De Ruysscher, A. van der Salm, and et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer Radiother Oncol 104 2012 67 71
22. J.J. Lin, E.J. Gallagher, K. Sigel, and et al. Survival of patients with stage IV lung cancer with diabetes treated with metformin Am J Respir Crit Care Med 191 2015 448 454
23. I. Ahmed, A. Ferro, A. Cohler, and et al. Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation J Thorac Dis 7 2015 346 355
24. H. Yu, L. Yin, X. Jiang, and et al. Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies PLoS ONE 9 2014 e116327
25. H.D. Skinner, C.H. Crane, C.R. Garrett, and et al. Metformin use and improved response to therapy in rectal cancer Cancer Med 2 2013 99 107
26. Z.J. Zhang, and S. Li The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis Diabetes Obes Metab 16 2014 707 710
27. S. Jiralerspong, S.L. Palla, S.H. Giordano, and et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer J Clin Oncol 27 2009 3297 3302
28. P.J. Goodwin, J.A. Ligibel, and V. Stambolic Metformin in breast cancer: time for action J Clin Oncol 27 2009 3271 3273
29. H.D. Skinner, M.R. McCurdy, A.E. Echeverria, and et al. Metformin use and improved response to therapy in esophageal adenocarcinoma Acta Oncol 52 2013 1002 1009
30. A. Izzotti, R. Balansky, and F. D'Agostini Modulation by metformin of molecular and histopathological alterations in the lung of cigarette smoke-exposed mice Cancer Med 2014
31. H. Muaddi, S. Chowdhury, R. Vellanki, P. Zamiara, and M. Koritzinsky Contributions of AMPK and p53 dependent signaling to radiation response in the presence of metformin Radiother Oncol 108 2013 446 450
32. G. Rena, E.R. Pearson, and K. Sakamoto Molecular mechanism of action of metformin: old or new insights? Diabetologia 56 2013 1898 1906
33. F. Frasca, G. Pandini, L. Sciacca, and et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases Arch Physiol Biochem 114 2008 23 37
34. E.J. Gallagher, and D. LeRoith Diabetes, cancer, and metformin: connections of metabolism and cell proliferation Ann N Y Acad Sci 1243 2011 54 68
35. C. Algire, M. Zakikhani, M.J. Blouin, J.H. Shuai, and M. Pollak Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth Endocr Relat Cancer 15 2008 833 839
36. I. Ben Sahra, Y. Le Marchand-Brustel, J.F. Tanti, and F. Bost Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9 2010 1092 1099
37. E. Petroulakis, Y. Mamane, O. Le Bacquer, D. Shahbazian, and N. Sonenberg MTOR signaling: implications for cancer and anticancer therapy Br J Cancer 94 2006 195 199
38. L. Li, M. Hu, H. Zhu, W. Zhao, G. Yang, and J. Yu Comparison of 18F-fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer Clin Lung Cancer 11 2010 335 340
39. D. Iliopoulos, H.A. Hirsch, and K. Struhl Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types Cancer Res 71 2011 3196 3201
40. G.Z. Rocha, M.M. Dias, E.R. Ropelle, and et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth Clin Cancer Res 17 2011 3993 4005
41. A.M. Dingemans, W.W. Mellema, H.J. Groen, and et al. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation Clin Cancer Res 19 2013 743 751
42. F.H. Groenendijk, W.W. Mellema, E. van der Burg, and et al. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation Int J Cancer 136 2015 1434 1444
43. M.M. Zanders, P.A. Vissers, and L.V. van de Poll-Franse Association between metformin use and mortality in patients with prostate cancer: explained by confounding by indication? J Clin Oncol 32 2014 701
44. A. Addeo, and C. Comins Optimal concurrent chemoradiotherapy regimen in non-small-cell lung cancer: prospective, randomized data still required J Clin Oncol 33 2015 2928